

A Review of Vibriosis in Fisheries: Public Health Importance

Azhar Muhammad Helmi¹, Akhmad Taufiq Mukti², Agoes Soegianto³ and Mustofa Helmi Effendi^{4*}

¹Postgraduate Student on Faculty of Fisheries and Marine, Universitas Airlangga.

²Department of Fish Health Management & Aquaculture, Faculty of Fisheries and Marine, Universitas Airlangga.

³Department of Biology, Faculty of Sciences and Technology, Universitas Airlangga.

⁴Halal Research Center, Universitas Airlangga.

Jl. Mulyorejo, Halal Research Center Unair, Kampus C UNAIR, Surabaya 60115

*Corresponding author Email: mheffendi@yahoo.com

ABSTRACT

Spp vibrio. This is a gram-negative bacteria which causes human and animal vibriosis. In public health, vibriosis is classified as an essential zoonotic disease. In humans, vibriosis is broken down into two groups of cholera and non-cholera infections. Cholera is a giddy tummy complaint that causes substantial mortality and dying in all the world. Vibrio spp noncholera. Occupy moderate to big salinity environments and can be seen in sea water and fish. These germs are the very vital pathogens in humans from the environment that come from aquatic and marine habitats. Efforts to control vibriosis in fish farming activities still rely on the use of drugs or antibiotics. Some of the antibiotics commonly used in aquaculture in Indonesia are oxytetracycline, chloramphenicol, erytromycin, streptomycin, neomycin, and enrofloxacin. These types of germicidal are generally used to treat germs illness in fish and shrimp through oral or immersion. However, the use of antibiotics for a certain period of time can cause the fish's body to develop resistance to pathogenic bacteria, polluting the environment and eventually killing the non-target organisms. High antibiotic use can lead to increased germicidal resistance. Awareness raising is critical to limiting inappropriate germicidal use. The goal of this analysis is to reduce the rising and emergence of antibiotic hospitality in *V. cholerae*, the ecology of germicidal hospitality genes, the antibiotic resistance mechanisms and the genomic parts involved in the spread of antibiotic hospitality.

Keywords: Public health, Antibiotic resistance, *Vibrio* spp, Vibriosis

Correspondence:

Mustofa Helmi Effendi

⁴Halal Research Center, Universitas Airlangga.

Jl. Mulyorejo, Halal Research Center Unair, Kampus C UNAIR, Surabaya 60115

*Corresponding author Email: mheffendi@yahoo.com

INTRODUCTION

Spp vibrio. is a gram-negative bacterium causing human and animal vibriosis [1]? In humans, vibriosis is broken down into two groups of cholera and non-cholera infections. [2] The illness is an inner disease produced by the *Vibrio cholerae* germs. Cholera transmission through food, drink contaminated by the bacteria *Vibrio cholerae*. Or contact with a cholera carrier. In the small intestine, the *Vibrio cholerae* bacteria will act by removing the toxin in the intestinal tract, resulting in diarrhea accompanied by acute and severe vomiting [3]. Non-cholera, such as *V. non-sporeforming* and *V. Vulnificus*, can cause vibriosis that is an infection with various clinical expression laying on the pathogenic species, infection mechanism and susceptibility to the host. Non-cholera bacteria may cause mild gastroenteritis or primary septicemia such as septicemia following ingestion of contaminated raw or undercooked food, while exposure to contaminated water to skin wounds may cause wound infection that may lead to secondary septicemia. *Vibrio* spp noncholera. Occupy moderate to high salinity environments, and can be found in sea water and fish. These bacteria are biologically significant human pathogens.

Wild fishing is important for food security in developing countries [5], particularly in African countries where aquaculture is still neglected and fish provide a large proportion of food based on animals [6]. In 2009, the region ranked second only to Asia in a ratio of 18.5 vs. 23 per cent of total animal protein provided by fish [7]. Besides their vital role in giving big quality power, fish also provide difference big fatty acids and inner micronutrients-including vitamins B and D, phosphorus,

power that rise the overall health [8]. Micronutrients are highly bioavailable in fish and easily accessible from other sources of food, in particular for the poor [9]. Alternatively, fish consumption increases micronutrient absorption from plant foods [8]. As a outcome, the use of fish in food-based nutrition initiatives to counter malnutrition is increasing [10-13].

Fishery is an important field in a country's food security, where the fisheries system plays a major role in spreading cholera to humans[14]. Cholera disease is a major public health threat, causing 2,9 million deaths and 98,000 deaths worldwide from 2008 to 2012[15]. *Vibrio cholerae* is found in various freshwater fish that are commonly consumed. Besides that *V. cholerae* is also resistant to heavy metals. Efforts to control vibriosis in fish farming activities still rely on the use of drugs or antibiotics. Some of the 2 antibiotics commonly used in aquaculture in Indonesia are oxytetracycline, chloramphenicol, erytromycin, streptomycin, neomycin, and enrofloxacin. These types of antibiotics are generally used to treat bacterial diseases in fish and shrimp through oral or immersion. The use of antibiotics for a certain period of time can cause problems with pathogenic bacteria resistance to these antibiotics in the fish body, polluting the environment which can eventually kill non-target organisms [16].

The emergence of antibiotic resistance is a good important several parts and several methods may affect the frequency of its occurrence, including the environment, density of microbial communities in some habitats, patterns of antibiotic use in health, livestock, food, and agriculture [17]. A variety of processes such as

transformation, conjugation, transduction, and outer membrane vesicle fusion (OMV) mediating horizontal gene transfer (HGT) are the key ways for the rapid emergence of antimicrobial resistance (AMR) pathogenic isolates [18]. Environmental factors, particularly compounds that induce germs responses that modulate HGT, are very important for the exchange of genetic material like AMR genes between bacteria in different species [19,20]. The prevalence of *V. cholerae*, which is AMR in nature, has maked steadily in recent decades and has spread throughout the world as a outcome of overuse and misuse of antibiotics in different industries [21, 22]. The rapid spread of resistance among pathogenic bacteria, including *V. cholerae*, is now a major challenge to both public health and the production of new antimicrobials by pharmaceutical companies. The aim of this analysis is to investigate the emergence and spread of germicide hostility in *V.*

OVERVIEW OF VIBRIO

Several species of vibrio have been claimed to infect infection in humans and aquatic animals, while a little count of other species have been used in cultivation as probiotics[23,24]. The Vibrio genus consisted of 14 different classes based on multilocus sequence analysis (MLSA): Clade has recently proved to be quite distinct and members have been amused into a fresh genus *Aliivibrio*[26].

The Harveyi class consisted originally of eight beings. In the Harveyi clade two more species have recently been identified, namely *Vibrio communis* and *V. owensii* [27,28]. Some of the species in the clade, however, show more than 99 percent similarity of 16S rRNA gene sequence [29,30, 31]. Harveyi Clade members occupy different ecological niches in the marine environment [32,33]. *V. cholerae* and *V. parahaemolyticus* are pathogenic in humans. *V. vulnificus* is a modern human-made pathogen. Such bacteria cause wound inflammation, gastroenteritis, or primary septicemia[34] syndrome. The *V. parahaemolyticus* strain is highly used in studies of molecular and environmental evolution and may be useful in identifying the food products involved during epidemiological research. There are many techniques available for subtypes. Serotyping is the main and ancient method of isolate differentiation. Since many isolates (especially for K antigens) could not be eliminated, however, serotype alone did not provide a high discriminatory capacity. Several studies have employed multiple typing methods on a collection of specific isolates to assess the ability of these methods to differentiate between essentially the same or very different isolate groups. While there are several accurate and selective subtype methods available for *V. parahaemolyticus*, many methods may need to be used together to better understand the genetic interaction between isolates and to distinguish specific strains[35,36].

V. cholerae is the most common cause of cholera in the world, with mortality rates reported in most countries at 50 percent or greater. This is of particular concern in places where shells are consumed raw or undercooked, although there is significantly increased incidence of fishing-related wound infections. This contain main areas which had not previously reported *V. cholerae*'s presence. *Vulnificus* or its contamination, likely due to higher surface sea water temperatures and lower salinity. Many people with primary septicemia have a chronic underlying condition that leads to an immunocompromised status. Nevertheless, in fact, people

with a potentially lethal wound infection usually do not have the underlying illness[34].

VIBRIOSIS

Cholera is considered as one of the oldest diseases and is still main burden in developing countries[37, 38]. A 12-year Florida study found that *V. Vulnificus* was the most common cause of primary septicemia among all species of *Vibrio*, accounting for 75 (64 per cent) of 118 cases, with a mortality rate of 56 per cent[39-42]. In another, wider epidemiological study of *V.* 23 countries confirmed to CDC *vulnificus* infection[43-47], a total of 422 *V. vulnificus* infections acquired between 1988 and 1996. Eighty-six per cent of all study patients were males [50,51,52]. The emergence of antibiotic resistance is a good important several parts and several methods may affect the frequency of its occurrence, including the environment, density of microbial communities in some habitats, patterns of antibiotic use in health, livestock, food, and agriculture. All *V.*-caused were wound infection (45 per cent), primary septicemia (43 per cent), gastroenteritis (5 per cent) and undetermined infection (7 per cent). *Vulnibus* [54,55,56]. Primary septicemia patients usually have underlying liver disease, and 96 percent acquire infection after eating raw oysters harvested from the Gulf of Mexico [57-61]. When septicemia happened, 61 per cent of cases resulted in the death of the patient [62,63].

VIBRIO TRANSMISSION FROM FISHERIES

Fish also indirectly promotes being food caring and well-shaped, with revenue from the selling of fish used to buy food or to give permission to education services and health [64,65]. Most rural households are interested in fishing as section of a high strategy for diversification of their livelihoods, mixing diverse economic activities to mitigate risks and cope with shocks [66]. Employment and fishing income will improve household economic resilience and prevent increased deprivation, with the position of this safety net arguing that it is a significant contribution to small-scale fisheries [67].

Food contamination remains a problem around the world. New hazards have been created by recent developments in food production and processing techniques as well as by recent changes in food consumption trends. Consumption of untreated water and raw seafood in summer is another epidemiological evidence of *V. cholerae* transmission [68]. The research was performed to isolate, classify and evaluate the sensitivity of *V. cholerae* to antibiotics in different species of fish. In 1883 Robert Koch first identified *V. cholerae*, the causative agent for cholera. The widely distributed free-living organism *Vibrio* with highly motile Gram-negative curves or stems with one polar flagellum, and most oxidase positive species [69]. When an affected person's human waste flows into water supplies to the community [70]. In different studies, *V. cholerae* incidence sampling was carried out from different sites to provide good opportunities for isolation of different bacteria and to determine the greater incidence of different foodstuffs, in sampling was carried out in local target markets. Different types of marine fish that exist, study the types of fish selected showed the presence of target bacteria, this indicates the presence of water pollution related with the prevalence of *V. cholerae*. The biochemical tests that were carried out revealed the phenotypic similarities of the two species observed in the results of the oxidase test, TSI, catalase, and Voges-Proskauer methyl red [71] confirmed that the tests that had been applied in this study were able to efficiently

differentiate these species. Thus, for the detection of isolate species, conventional biochemical tests show low efficiency. Molecular recognition is an important method in clinical diagnosis; PCR-based detection targets different areas of DNA, for bacterial strain recognition. In addition, PCR allowed the identification of viable but non-cultivable strains [72] in the sample, amplified the 16S rRNA gene and showed good results. It is less labor intensive and much faster than conventional methods, and that is the reason its application is increasing among researchers [73]. Antibiogram profile revealed that all isolates showed multi-drug resistance to amoxicillin and nitrofurantoin. And they are susceptible to residual antibiotics used in this study that are commonly used to treat cholera infections. Mukhopadhyay et al. [74] reported the ineffectiveness of cotrimoxazole and furazolidone for treating patients with *V. cholerae* O1 infection and the emergence of nalidixic acid resistance among O1 strains from Calcutta patients [75], isolated and reported tetracycline resistant strains in Kolkata in 2005. There is agreement among all tested *Vibrio* strains between the results which demonstrated high individual and multiple antibiotic resistance, and other investigators [76,77]. The main source for ion therapy for microbial infections is antibiotics. Nevertheless, by cultivating antibiotic resistance [78], the high genetic diversity of micro-organisms helps them to easily escape antibiotic behavior. One research showed that all *Vibrio* strains contained antibiotic-resistant genes [79]. Thungapathra et al. showed that 43 strains contained R-plasmid in a total of 94 *V. cholerae* isolates and had resistance to ampicillin, neomycin, tetracyclines, gentamicin, streptomycin, sulfonamides, furazolidone and chloramphenicol[80]. Given other well-reported cases of *Vibrio* outbreaks the isolates were not much resistant. Hence, the development of new and innovative antimicrobial drugs is urgently needed to effectively eradicate microorganism-producing disease [81-84] have also recently been isolated from cholera. Shitrit-Laviad et al. Reported high minimum inhibitory concentrations (MIC) of *V. cholerae* isolates ($n = 48$) from the fish gut to doxycycline (MIC 90 of 16 $\mu\text{g}/\text{mL}$)[85].

V. cholerae O1 and serogroup O139 produce cholera toxin (CT) that changes the permeability of epithelial cell membranes in the small intestine, resulting in uncontrolled water and electrolyte secretion into the colon and large intestine [86,87]. Virulence is a colonization and adherence factor feature [88,89], which can enhance the CT effect. Generally the onset is abrupt and can be related to vomiting. The American Public Health Association[90] reports that the infection is typically asymptomatic in most cases, or may cause moderate diarrhea. All of which can lead to shock and rapid death [91,92]. In cases of severe dehydration (cholera gravis; associated diarrhea stool equivalent to 1 L / h) [93] [90,92].

ANTIBIOTIC RESISTANCE ON FISHERIES

For more than six decades, antibiotics have been seen as a solution for curing bacterial infections. Microorganisms, however, have developed different ways of combating the new drugs that are being used against them. In recent years, the threat of infection caused by resistance-developing microbes has increased rapidly, with more than 50,000 deaths in Europe and the United States alone annually. In developing and underdeveloped countries the number of deaths from such infection is much higher[94]. The patterns of antimicrobial resistance (AMR) are significantly different globally. In particular, in Europe,

most bloodstream-related infections are caused by *Staphylococcus aureus*. In developing and underdeveloped countries, the emergence of high resistance to tuberculosis (TB), malaria, and HIV has been documented.

The AMR pattern varies from country to country in relation to how much antimicrobial drug was used [95, 96, 97]. Antibiotic consumption has increased globally by 36% from 2000 to 2015 with significant variations across regions [98]. The most common Gram-negative AMR pathogens are the most common treatment for *Pseudomonas aeruginosa*, *Salmonella enterica*, *Vibrio cholerae*, *Klebsiella pneumonia*, and aminopenicillin *Escherichia coli* [99, 100, 101]. In 2010, India ranked first in antibiotic use globally with an average of 12.9 • 109 units [102, 103]. Treatment of antimicrobial agents will effectively monitor the occurrence and prevalence of pathogenic microorganisms caused by infectious diseases. The improper use of antimicrobial drugs in society, however, leads to the production of antimicrobial-resistant bacteria and poses a possible threat to human health due to the spread of antimicrobial resistance [103, 104, 105].

The aquatic environment is a reservoir for *V. cholerae* and can be a major resistant strain source[106]. A variety of earlier studies focused on detecting [107]. The Bhuyan et al. 107 V also stated that. Various levels of resistance to AMP, cotrimoxazole, nalidixic acid, polymyxin-B, streptomycin (STR), ciprofloxacin, and tetracyclines (TET) have been observed in Indian cholerae from various aquatic environments (including water from the river, water from the canal, water from the pond and water from the hand pump)[108]. Antimicrobial-resistant *V. cholerae* were also reported isolated from animals in aquaculture such as shrimp and shellfish. He and others. Studied 42 *V. cholerae* isolates collected in Shanghai , China in 2013 and 2014 and found 33.3%, 21.4%, 19.1%, 9.5%, and 9.5% rifampin (RIF), STR, KAN, AMP, and TET isolates. A total of 25 isolates received an MDR.

Antibiotic treatment is recommended in patients with cholera after the initial fluid deficit has been recovered and vomiting prevented. Between the 1940s and 1960s, streptomycin [110,111] and chloramphenicol [112,113] were among the earliest effective antibiotics used in the treatment of cholera. In Calcutta in 1962 [114] the use of tetracyclines in the treatment of cholera was shown. Because of comparable results in various clinical trials [115,116], furazolidone is considered an alternative to tetracycline in treating children with cholera [112]. During the 1970s cholera treatment was introduced with Sulphamethoxazole-trimethoprim- (SXT) [117]. In Lima, Peru, both SXT and tetracycline therapeutic regimens performed equally well in patients with cholera [118]. Tetracycline, chloramp henicol, and SXT[119-121] were equally effective for the elimination of *V. cholerae* from cholera patients [122]. Because of its unnecessary excretion and the emergence of organisms that are resistant to certain drugs used to treat patients, chemoprophylaxis is generally not recommended in cholera control programmes.

An brilliant essential of late germ evolution is the emergence of XDR and MDR *V. cholerae*. Resistance to one or more antibiotics reported in *V. cholerae* during the 1960s was largely due to the acquisition of spontaneous mutations in drug targets such as DNA gyrase, topoisomerase, RNA polymerase b-subunit (RpoB) and ribosomal protein 12 subunits [123,124]. Nevertheless,

recent studies have shown that the emergence of MDR and XDR *V. cholerae* is primarily facilitated by autonomous plasmids including transposable genetic elements [125,126, 127]. Furthermore, *V. cholerae*'s resistance profile has shifted intensively over the last five decades [128]. Tanzania was documented during 1977-78 mainly through the use of prophylactic drugs [127]. Due to the existence of the unstable mega-plasmid-C incompatibility complex (IncC) [129] this resistance was detected. In 1994, tetracycline-resistant *V. cholerae* O1 caused the deaths of some 12,000 Rwandan refugees in Goma, East Zaire [130]. Tetracycline and doxycycline are antibiotics used in treating cholera patients in this worst epidemic. Classical biotype isolates from the southern coastal region of Bangladesh were found to be resistant to tetracyclines during 198-89, while the isolated El Tor biotypes from the same area were sensitive [131]. Even *V. cholerae* serogroup O139 which emerged from Karachi in 1993 was reported to be tetracycline-resistant in Pakistan [132]. From the early 1990s, there began to appear drastic increases in resistance to ampicillin, nalidixic acid, chloramphenicol and tetracyclines [133]. Recent findings suggest that the majority of *V. cholerae* clinical isolates are immune to almost all antibiotics used routinely [125,134]. The antimicrobial resistance coding role has also been established as being in self-infectious plasmids. First described in 1996 was the emergence of MDR on *V. cholerae* belonging to the serogroup O139. A 100-Kb ICE called the SXT element that carries several resistance genes against Sulfamethoxazole, Trimethoprim, and Streptomycin has shown to cause resistance. Some of *V.*'s environmental strains were further found. Isolated cholerae also harbored SXT elements in their genomes during 1986 and displayed resistance to ampicillin, SXT, streptomycin and furazolidone [135]. Furthermore, mobile integrons physically connected to conjugative plasmids or transposons also transmit various coding functions worldwide for resistance to *V. cholerae* isolates in clinical and environmental conditions.

CONCLUSION

Vibrio spp. has always been a public health problem that occurs around the world, which comes from fisheries. The spread of *Vibrio* is very widespread and persistent in the environment, thus increasing the difficulty in reducing the spread of *Vibrio* spp. *Vibrio* spp. it can even cause death in humans and animals. Apart from this, the emergence of antibiotic resistance in *Vibrio* is a major challenge in terms of effective treatment for the *Vibrio* infection. One of the most important and effective steps to avoid the spread of antibiotic resistance in the fisheries sector is to restrict the use of antibiotics in fish feed.

ACKNOWLEDGMENT

This review was supported by the **Direktorat Riset dan Pengabdian Masyarakat, Deputi Bidang Penguatan Riset dan Pengembangan Kementerian Riset dan Teknologi/ Badan Riset dan Inovasi Nasional, Indonesia** in fiscal year 2020 with grant number : 756/UN3.14/PT/2020.

REFERENCES

1. Morris JG. Cholera and other types of vibriosis: a story of human pandemics and oysters on the half shell. *Clin. Infect.* 2003; Dis 37, 272-280.
2. Baker-Austin C, Oliver JD, Alam M, Ali A, Waldor MK, Qadri F, Martinez-Urtaza J. *Vibrio* spp. infections. *Nat Rev Dis Primers* 2018; 48
3. Sawasvirojwong S, Srimanote P, Chatsudhipong V, Muanprasat C. An Adult Mouse Model of *Vibrio cholerae*-induced Diarrhea for Studying Pathogenesis and Potential Therapy of Cholera, *Journal of Neglected Tropical Disease* 2013
4. Howard-Jones, N. Robert Koch and the Cholera vibrio: a centenary. *Br. Med. J. Clin.* 1984; Res. Ed 288, 379-281
5. Hall SJ, Hilborn R, Andrew NL, Allison, EH. Innovations in Capture Fisheries are An Imperative for Nutrition Security in the Developing World. *Proceedings of the National Academy of Sciences.* 2013;110: 8393-8398.
6. Beveridge MCM, Thilsted SH, Phillips MJ, Metian M, Troell,M, Hall SJ. Meeting the Food and Nutrition Needs of the Poor: The Role of Fish and Opportunities and Challenges Emerging from the Rise of Aquaculture. *Journal of Fish Biology.* 2013; 83: 1067-1084.
7. Tacon AGJ, and Metian M. Fish Matters: Importance of Aquatic Foods in Human Nutrition and Global Food Supply. *Reviews in Fisheries Science.* 2013;21: 22-38.
8. Kawarazuka N, and Béné C. The Potential Role of Small Fish Species in Improving Micronutrient Deficiencies in Developing Countries: Building Evidence. *Public Health Nutrition.* 2011;14: 1927- 1938.
9. Thilsted SH, Thorne-Lyman,A, Webb P, Bogard JR, Subasinghe R, Phillips MJ, Allison EH. Sustaining Healthy Diets: The Role of Capture Fisheries and Aquaculture for Improving Nutrition in the Post-2015 Era. *Food Policy.* 2016; 61: 126-131.
10. Longley C, Thilsted SH, Beveridge M, Cole S, Nyirenda DB, Heck S, Hother AL. The role of fish in the first 1,000 days in Zambia. *IDS Special Collection.* 2014; <http://opendocs.ids.ac.uk/opendocs/handle/123456789/4384>.
11. Roos N, Wahab MA, Chamnan C, Thilsted SH. The Role of Fish in Food-Based Strategies to Combat Vitamin a and Mineral Deficiencies in Developing Countries. *The Journal of Nutrition.* 2007;137: 1106-1109.
12. Toledo A, Burlingame B. Biodiversity and Nutrition: A Common Path Toward Global Food Security and Sustainable Development. *Journal of Food Composition and Analysis.* 2006; 19: 477-483.
13. Gibson RS, Yeudall F, Drost N, Mtitimuni BM, Cullinan TR. Experiences of a Community-Based Dietary Intervention to Enhance Micronutrient Adequacy of Diets Low in Animal Source Foods and High in Phytate: A Case Study in Rural Malawian Children. *The Journal of Nutrition.* 2003; 133: 3992S-3999S.
14. Vezzulli L, Pruzzo C, Huq A, Colwell RR. Environmental reservoirs of *Vibrio cholerae* and their role in cholera. *Environ Microbiol Rep.* 2010; 2:27-33
15. Ali M, Nelson AR, Lopez AL, and Sack DA. Updated global burden of cholera in endemic countries. *PLoS Negl. Trop. Dis.* 9:e0003832. doi: [10.1371/journal.pntd.0003832](https://doi.org/10.1371/journal.pntd.0003832). 2015

16. Guo JJ, Liu KF, Cheng SH, Chang C, Lay JJ, Hsu YO, Yang JY, Chen TY. Selection of probiotic bacteria for use in shrimp larvi culture. *Aquaculture Research*. 2009; 40:609–618.
17. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet* 2016;387:176–87.
18. Bag S, Ghosh TS, Banerjee S, Mehta O, Verma J, Dayal M, et al. Molecular insights into antimicrobial resistance traits of commensal human gut microbiota. *Microb Ecol* 2019;772:546–57.
19. von Wintersdorff CJ, Penders J, van Niekerk JM, Mills ND, Majumder S, van Alphen LB, et al. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. *Front Microbiol* 2016;7:173.
20. Pant A, Anbumani D, Bag S, Mehta O, Kumar P, Saxena S, et al. Effect of LexA on chromosomal integration of CTXvarphi in vibrio cholerae. *J Bacteriol* 2016;1982:268–75.
21. Nakaya R, Nakamura A, Murata Y. Resistance transfer agents in Shigella. *Biochem Biophys Res Commun* 1960;3:645–59.
22. Watanabe T. Infective heredity of multiple drug resistance in bacteria. *Bacteriol Rev* 1963;27:87–115.
23. Balca'zar JL, de Blas I, Ruiz-Zarzuelal, Cunningham D, Vendrell D, Mu'quiz, J. L. The role of probiotics in aquaculture. *Vet. Microbiol.* 2006;114, 173–186.
24. Pérez T, et al. Host-microbiota interactions within the fish intestinal ecosystem. *Mucosal Immunol* 2010;3, 355–360.
25. Sawabe T, Kita-Tsukamoto K, Thompson FL. Inferring the evolutionary history of vibrios by means of multilocus sequence analysis. *J Bacteriol*. 2007;189, 7932–7936.
26. UrbanczykH, Ast JC, Higgins MJ, Carson J, Dunlap PV. Reclassification of *Vibrio fischeri*, *Vibrio logei*, *Vibrio salmonicida* and *Vibrio wodanis* as *Aliivibrio fischeri* gen. nov., comb. nov., *Aliivibrio logei* comb. nov., *Aliivibrio salmonicida* comb. nov. and *Aliivibrio wodanis* comb. nov. *Int J Syst Evol Microbiol*. 2007;57, 2823–2829.
27. Cano-Go'mez A, Goulden EF, Owens L, & Høj L. *Vibrio owensii* sp. nov., isolated from cultured crustaceans in Australia. *FEMS Microbiol Lett*. 2010;302, 175–181.
28. Chimetto LA, Cleenwerck I, Alves N, Jr Silva BS, Brocchi M, Willems A, De Vos P, Thompson FL. *Vibrio communis* sp. nov., isolated from the marine animals *Mussismilia hispida*, *Phyllogorgia dilatata*, *Palythoa caribaeorum*, *Palythoa variabilis* and *Litopenaeus vannamei*. *Int J Syst Evol Microbiol*. 2011;61, 362–368.
29. Fukui Y, Sawabe T. Improved one-step colony PCR detection of *Vibrio harveyi*. *Microbes Environ*. 2007;22, 1–10.
30. Owens L, Busico-Salcedo M. *Vibrio harveyi*: pretty problems in paradise. In The Biology of Vibrios, pp. Edited by F. L. Thompson, B. Austin & J. Swings. Washington, DC: American Society for Microbiology. 2006;266–280
31. Thompson FL, Gomez-Gil B, Vasconcelos ATR, Sawabe T. Multilocus sequence analysis reveals that *Vibrio harveyi* and *V. campbellii* are distinct species. *Appl Environ Microbiol*. 2007;73, 4279–4285.
32. Yoshizawa S, Wada M, Kita-Tsukamoto K, Ikemoto E, Yokota A, Kogure K. *Vibrio azureus* sp. nov., a luminous marine bacterium isolated from seawater. *Int J Syst Evol Microbiol*. 2009;59, 1645–1649.
33. Austin B, Austin DA. *Bacterial Fish Pathogens: Disease of Farmed and Wild Fish*, 3rd edn. Berlin: Springer. 1999.
34. Oliver JD, Jones JL. *Vibrio parahaemolyticus* and *Vibrio vulnificus*. *Gastrointestinal Infections: Superficial*. 2015; 6610, 1169–1188
35. Martinez-Urtaza J, Baker-Austin C, Newton AE, Jones JL, Gonzalez-Aviles GD, DePaola A. Transoceanic spread of Pacific Northwest *Vibrio parahaemolyticus* strains. *N Engl J Med* 2013;369:15734.
36. Wong HC, Lin CH. Evaluation of typing of *Vibrio parahaemolyticus* by three PCR methods using specific primers. *J Clin Microbiol* 2001;39:423340.
37. World Health Organization. Cholera: the forgotten pandemic. World Health Organization, Geneva, Switzerland. 2018; <https://www.who.int/cholera/the-forgotten-pandemic/en/>.
38. Lipp EK, Huq A, Colwell RR. Effects of global climate on infectious disease: the cholera model. *Clin Microbiol Rev*. 2002; 15:757–770. <https://doi.org/10.1128/CMR.15.4.757-770.2002>.
39. WHO. WHO Cholera Fact Sheet. WHO. 2015; published online July. <http://www.who.int/mediacentre/factsheets/fs107/en/>.
40. Kaper JB, Morris JG Jr, Levine MM. *Cholera*. *Clin. Microbiol. Rev*. 8, 48–86.
41. Deshayes, S., Daurel, C., Cattoir, V., Parienti, J. J., Quilici, M. L., and de La Blanchardière, A. 2015. Non-O1, non-O139 *Vibrio cholerae* bacteraemia: case report and literature review. *SpringerPlus* 4:575.1995; doi: 10.1186/s40064-015-1346-3
42. Lewin SM. "Zoological microhabitats of *Vibrio cholerae*," in *Cholera and the Ecology of Vibrio cholerae*, eds B. S. Drasar and B. D. Forrest London: Chapman and Hall, 228–254. 1996; doi: 10.1007/978-94-009-1515-2_7
43. Kirchberger PC, Orata FD, Barlow EJ, Kauffman KM, Case RJ, Polz MF, et al. A small number of phylogenetically distinct clonal complexes dominate a coastal *Vibrio cholerae* population. *Appl. Environ. Microbiol.* 2016;82, 5576–5586. doi: 10.1128/AEM.01177-16
44. Huq A, Small EB, West PA, Huq MI, Rahman R, Colwell RR. Ecological relationships between *Vibrio cholerae* and planktonic crustacean copepods. *Appl. Environ. Microbiol.* 1983;45, 275–283.
45. Broza M, Halpern M. Chironomids egg masses and *Vibrio cholerae*. *Nature*. 2001; 412:40. doi: 10.1038/35083691

46. Halpern M, Broza YB, Mittler S, Arakawa E, Broza M. Chironomid egg masses as a natural reservoir of *Vibrio cholerae* nonO1 and non-O139 in freshwater habitats. *Microb. Ecol.* 2004; 47, 341-349. doi: 10.1007/s00248-003-2007-6
47. Halpern M, Senderovich Y, Izhaki I. Waterfowl — the missing link in epidemic and pandemic cholera dissemination? *PLoS Pathog.* 2008;4:e1000173. doi: 10.1371/journal.ppat.1000173
48. Halpern M, Izhaki I. "The environmental reservoirs and vector of *Vibrio cholerae*," in *Handbook of Disease Outbreaks: Prevention, Detection and Control*, eds A. Holmgren and G. Borg New York, NY: Nova Science Publishers, . 2010; 309–320.
49. Oliver JD. *Vibrio vulnificus*. In: Thompson FL, Austin B, Swing J, editors. *Biology of Vibrios*. Washington, DC: American Society for Microbiology; 2006. p. 34966.
50. Oliver JD. *Vibrio vulnificus*. In: Belkin S, Colwell RR, editors. *Oceans and Health: Pathogens in the Marine Environment*. New York: Springer Science; 2006. p. 25376.
51. Bisharat N, Agmon V, Finkelstein R, Raz R, Ben-Dror G, Lerner L, et al. Clinical, epidemiological, and microbiological features of *Vibrio vulnificus* biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. *Lancet* 1999;354:14214.
52. Oliver JD, Warner RA, Cleland DR. Distribution of *Vibrio vulnificus* and other lactose-fermenting vibrios in the marine environment. *Appl Environ Microbiol* 1983;45:98598.
53. Oliver JD. *Vibrio vulnificus*: death on the half shell. A personal journey with the pathogen and its ecology. *Microb Ecol* 2013;65:7939.
54. Hoi L, Larsen JL, Dalsgaard I, Dalsgaard A. Occurrence of *Vibrio vulnificus* biotypes in Danish marine environments. *Appl Environ Microbiol* 1998;64:713.
55. Barbieri E, Falzano L, Fiorentini C, Pianetti A, Baffone W, Fabbri A, et al. Occurrence, diversity, and pathogenicity of halophilic *Vibrios* spp. and non-O1 *Vibrio cholerae* from estuarine waters along the Italian Adriatic coast. *Appl Environ Microbiol* 1999;65:274853.
56. Ghosh HK, Bowen TE. Halophilic vibrios from human tissue infections on the Pacific coast of Australia. *Pathology* 1980;12:397402.
57. Hor LI, Gao CT, Wan L. Isolation and characterization of *Vibrio vulnificus* inhabiting the marine environment of the southwestern area of Taiwan. *J Biomed Sci* 1995;2:3849.
58. Hoyer J, Engelmann E, Liehr RM, Distler A, Hahn H, Shimada T. Septic shock due to *Vibrio vulnificus* serogroup O4 wound infection acquired from the Baltic Sea. *Eur J Clin Microbiol Infect Dis* 1995;14:10168.
59. Landgraf M, Leme KBP, Garcia-Moreno ML. Occurrence of emerging pathogenic *Vibrios* spp. in seafood consumed in São Paulo City. *Braz Rev Microbiol* 1996;27:12630.
60. Melhus A, Holmdahl T, Tjernberg I. First documented case of bacteremia with *Vibrio vulnificus* in Sweden. *Scand J Infect Dis* 1995;27:812.
61. Veenstra J, Rietra PJ, Coster JM, Slaats E, Dirks-Go S. Seasonal variations in the occurrence of *Vibrio vulnificus* along the Dutch coast. *Epidemiol Infect* 1994;112:28590.
62. Hlady WG, Klontz KC. The epidemiology of *Vibrio* infections in Florida, 1981–1993. *J Infect Dis* 1996;173:117683.
63. Shapiro RL, Altekkruse S, Hutwagner L, Bishop R, Hammond R, Wilson S, et al. The role of Gulf Coast oysters harvested in warmer months in *Vibrio vulnificus* infections in the United States, 1988–1996. *J Infect Dis* 1998;178:7529.
64. Béné C, Friend RM. Poverty in Small-Scale Fisheries: Old Issue, New Analysis. *Progress in Development Studies*. 2011; 11: 119–144.
65. Kawarazuka N, Béné C. Linking Small-Scale Fisheries and Aquaculture to Household Nutritional Security: An Overview. *Food Security*. 2010;2: 343–357.
66. Smith LED, Nguyen Khoa S, Lorenzen K. Livelihood Function of Inland Fisheries: Policy Implications in Developing Countries. *Water Policy*. 2005;7: 359–383.
67. Béné C, Hersoug B, Allison EH. Not by Rent Alone: Analysing the Pro-Poor Functions of Small-Scale Fisheries in Developing Countries. *Development Policy Review*. 2010; 28: 325–358.
68. Gilmour MW, Martel-Laferrière V, Lévesque S, Gaudreau C, Bekal S, Nadon C, et al. *Vibrio cholerae* in traveler from Haiti to Canada. *Emerg Infect Dis* 2011;176:1124–5.
69. Lee JH, Rho JB, Park KJ, Kim CB, Han YS, Choi SH, et al. Role of flagellum and motility in pathogenesis of *Vibrio vulnificus*. *Infect Immun* 2004;728:4905–10.
70. Schild S, Lamprecht AK, Reidl J. Molecular and functional characterization of O antigen transfer in *Vibrio cholerae*. *J Biol Chem* 2005;28027:25936–47.
71. Kaysner CA, DePaola A Jr. *Vibrio cholerae*, *V. parahaemolyticus*, *V. vulnificus*, and other *Vibrio* sp. US Food and Drug Administration Bacteriological Analytical Manual Online. Washington, DC: US Food and Drug Administration; 2003.
72. Binsztein N, Costagliola MC, Pichel M, Jurquiza V, Ramírez FC, Akselman R, et al. Viable but nonculturable *Vibrio cholerae* O1 in the aquatic environment of Argentina. *Appl Environ Microbiol* 2004;7012:7481–6.
73. Teh CS, Chua KH, Thong KL. Simultaneous differential detection of human pathogenic and nonpathogenic *Vibrio* species using a multiplex PCR based on *gyrB* and *pntA* genes. *J Appl Microbiol* 2010;1086:1940–5.
74. Mukhopadhyay AK, Garg S, Nair GB, Kar S, Ghosh RK, Pajni S, et al. Biotype traits and antibiotic susceptibility of *Vibrio cholerae* serogroup O1 before, during and after the emergence of the O139 serogroup. *Epidemiol Infect* 1995;1153:427–34.
75. Roychowdhury A, Pan A, Dutta D, Mukhopadhyay AK, Ramamurthy T, Nandy RK, et al. Emergence of tetracycline-resistant *Vibrio cholerae* O1 serotype Inaba, in Kolkata, India. *Jpn J Infect Dis* 2008;612:128–9.

76. Ansari M, Raissy M. *In vitro* susceptibility of commonly used antibiotics against *Vibrio* sp. isolated from lobster *Panulirus homarus*. Afr J Microbiol Res 2010;423:2629-31.
77. Okoh AI, Igbinosa EO. Antibiotic susceptibility profiles of some *Vibrio* strains isolated from wastewater final effluents in a rural community of the Eastern Cape province of South Africa. BMC Microbiol 2010;101:143.
78. Leelaprakash G, Dass SM. Antimicrobial activity and phytochemical screening of methanol extract of *Enicostemma axillare*. Int J Pharm Pharm Sci 2012;41:342-8.
79. Ramachandran D, Bhanumathi R, Singh DV. Multiplex PCR for detection of antibiotic resistance genes and the SXT element: Application in the characterization of *Vibrio cholerae*. J Med Microbiol 2007;563:346-51.
80. Thungapathra M, Sinha KK, Chaudhuri SR, Garg P, Ramamurthy T, Nair GB, et al. Occurrence of antibiotic resistance gene cassettes aac 6'-lb, dfrA5, dfrA12, and ereA2 in class I integrons in non-O1, non-O139 *Vibrio cholerae* strains in India. Antimicrob Agents Chemother 2002;469:2948-55.
81. Suresh M, Arularasan S, Srikuamaran N. Screening on antimicrobial activity of marine gastropods *Babylonia zeylanica* Bruguière, 1789 and *Harpa conoidalis* Lamarck, 1822 from Mudosalodai, Southeast coast of India. Int J Pharm Pharm Sci 2012;44:552-6.
82. Halpern M, Izhaki I 2017 Fish as hosts of *Vibrio cholerae*. Front Microbiol 8:282
83. Senderovich Y, Izhaki I, Halpern M. Fish as reservoirs and vectors of *Vibrio cholerae*. 2010; PLoS One 5:e8607
84. Li T, Li M, Miao Y, Yang Y 2017 Distribution and virulence genes of pathogenic *Vibrio* in freshwater fish and their living environment in Chengdu in 2016. J Applied Prev Med 23:469-471 in Chinese
85. Laviad-Shitrit S, Sharaby Y, Izhaki I, Peretz A, Halpern M. Antimicrobial susceptibility of environmental non-O1/non-O139 *Vibrio cholerae* isolates. Front Microbiol. 2018; 9:1726
86. Colwell, RR. A voyage of discovery: cholera, climate and complexity. Environ. Microbiol. 2002;4 2, 67-69.
87. USAMRIID U.S. Army Medical Research Institute of Infectious Diseases. 1998. Medical Management of Biological Casualties. 3rd ed. U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland.
88. Merrell DS, Butler SM, Qadri F, et al. Host-induced epidemic spread of the cholera bacterium. Nature. 2002; 417 6, 642-645.
89. Kaper JB, Morris Jr JG, Levine MM. Cholera. Clin. Microbiol. 1995;Rev. 8 1, 48-86.
90. APHA American Public Health Association. Control of communicable diseases manual. In: Heymann, D.L. Ed., Official Report of the APHA. American Public Health Association, 800 I Street, Washington, . 2008; D.C 20001-3710.
91. Colwell RR. A voyage of discovery: cholera, climate and complexity. Environ. Microbiol. 2002;4 2, 67-69.
92. Ministry of Health and Population in Haiti/U.S. Centers for Disease Control and Prevention CDC, 2011. Haiti cholera training manual: a full course for healthcare providers Version 2.1, 2011.
93. Morris JG. Cholera-modern pandemic disease of ancient lineage. Emerg. Infect. . 2011; Dis. 17, 2099-2104.
94. Mackey TK, LiangBA, CuomoR, HafenR, BrouwerK, and LeeD. Emerging and re-emerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment. Clin. Microbiol. 2014; Rev. 27:949-979.
95. Effendi, M.H., Harijani, N., Budiarto, Triningtya, N.P., Tyasningsih, W. and Plumeriastuti, H. Prevalence of Pathogenic *Escherichia coli* Isolated from Subclinical Mastitis in East Java Province, Indonesia. Indian Vet. J., 2019; 96 (03) : 22- 25.
96. Putra, A. R. S., Effendi, M.H., Koesdarto, S., and Tyasningsih, W. Molecular Identification of Extended Spectrum Beta-Lactamase (ESBL) Producing *Escherichia coli* Isolated from Dairy Cows in East Java Province, Indonesia. Indian Vet. J. 2019; 96 (10): 26-30.
97. Wibisono, F.J. Sumiarto, B., Untari, T., Effendi, M.H., Permatasari, D.A., Witanningrum. A.M.. The Presence of Extended Spectrum Beta-Lactamase (ESBL) Producing *Escherichia coli* On Layer Chicken Farms In Blitar Area, Indonesia. BIODIVERSITAS, 2020; 21 (6): 2667-2671.
98. Van Boeckel TP, GandraS, AshokA, CaudronQ, GrenfellBT, LevinSA, LaxminarayanR. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect. 2014;Dis.14:742- 750.
99. Kristianingtyas, L., Effendi, M. H., Tyasningsih, W., Kurniawan, F. Genetic Identification of blaCTX-M Gene and blatem Gene on Extended Spectrum Beta Lactamase (ESBL) Producing *Escherichia coli* from Dogs. Indian Vet. J. 2020; 97 (01): 17-21.
100. Effendi, M. H., Bintari, I. G., Aksoro,E. B. and Hermawan. I. P. Detection of blaTEM Gene of *Klebsiella pneumoniae* Isolated from swab of food-producing animals in East Java. Trop. Anim. Sci. J. 2018; 41:174-178.
101. Wibisono, F.J., Sumiarto, B., Untari, T., Effendi, M.H., Permatasari, D.A., Witanningrum, A.M. CTX Gene of Extended Spectrum Beta-Lactamase (ESBL) Producing *Escherichia coli* on Broilers in Blitar, Indonesia. Sys Rev Pharm 2020;11(7): 396-403.
102. Laxminarayan, R, ChaudhuryRR. Antibioticresistance in India: drivers and opportunities for action. 2016;PLoS Med. 13:e1001974.
103. Woolhouse M, Farrar J. Policy: an intergovernmental panel on antimicrobial resistance. Nature. 2014; 509:555-557
104. Widodo, A., Effendi, M.H., Khairullah, A.R.Extended-spectrum beta-lactamase (ESBL)-producing *Eschericia coli* from livestock. Sys Rev Pharm 2020;11(7): 382-392.

105. Riwu, K.H.P., Effendi, M.H., Rantam, F.A. A Review of Extended Spectrum β -Lactamase (ESBL) Producing *Klebsiella pneumoniae* and Multidrug Resistant (MDR) on Companion Animals. *Sys Rev Pharm* 2020;11(7):270-277.
106. Baron S, Larvor E, Chevalier S, Jouy E, Kempf I, Granier SA, Lesne J. Antimicrobial susceptibility among urban wastewater and wild shellfish isolates of non-O1/non-O139 *Vibrio cholerae* from La Rance Estuary Brittany, France. 2017; *Front Microbiol* 8:1637.
107. Sulca MA, Orozco R, Alvarado DE. Antimicrobial resistance not related to 1,2,3 integrons and Superintegron in *Vibrio* spp. isolated from seawater sample of Lima Peru. *Mar Pollut Bull.* 2018; 131:370–377.
108. Bhuyan SK, Vairale MG, Arya N, Yadav P, Veer V, Singh L, Yadava PK, Kumar P. Molecular epidemiology of *Vibrio cholerae* associated with flood in Brahmaputra River valley, Assam, India. *Infect Genet Evol.* 2016; 40:352–356.
109. He Y, Tang Y, Sun F, Chen L. Detection and characterization of integrative and conjugative elements ICEs-positive *Vibrio cholerae* isolates from aquacultured shrimp and the environment in Shanghai, China. *Mar Pollut Bull.* 2015; 101:526–532.
110. Reimann HA, Chang GC, et al. Asiatic cholera; clinical study and experimental therapy with streptomycin. *Am J Trop Med Hyg* 1946;26:631–47.
111. Uylangco CV, Fabie AE, Mier SG, Santiago L. Oral streptomycin in the treatment of cholera. *J Philipp Med Assoc* 1965;41:763–9.
112. Chaudhuri RN, Ghosal S, Rai Chaudhuri MN. Chloromycetin in the treatment of cholera. *Ind Med Gaz* 1950;85:398–400.
113. Chakravarti HS, Mondal A, Mukherjee AM, Pal NG. Further observations on intravenous chloramphenicol in cholera. *J Indian Med Assoc* 1954;23:331–2.
114. Carpenter CC, Sack RB, Mondal A, Mitra PP. Tetracycline therapy in cholera. *J Indian Med Assoc* 1964;43:309–12.
115. Pierce NF, Banwell JG, Mitra RC, Caranasos GJ, Keimowitz RI, Thomas J, et al. Controlled comparison of tetracycline and furazolidone in cholera. *Br Med J* 1968;3:277–80.
116. Karchmer AW, Cirlin GT, Huq MI, Hirschhorn N. Furazolidone in paediatric cholera. *Bull World Health Organ* 1970;43:373–8.
117. Cash RA, Northrup RS, Mizanur Rahman AS. Trimethoprim and sulfamethoxazole in clinical cholera: comparison with tetracycline. *J Infect Dis* 1973;128:Suppl:749–53p.
118. Grados P, Bravo N, Battilana C. Comparative effectiveness of co-trimoxazole and tetracycline in the treatment of cholera. *Bull Pan Am Health Organ* 1996;30:36–42.
119. Gharagozloo RA, Naficy K, Mouin M, Nassirzadeh MH, Yalda R. Comparative trial of tetracycline, chloramphenicol, and trimethoprim-sulphamethoxazole in eradication of *Vibrio cholerae* El Tor. *Br Med J* 1970;4:281–2.
120. Pastore G, Rizzo G, Fera G, Schiraldi O. Trimethoprim-sulphamethoxazole in the treatment of cholera. Comparison with tetracycline and chloramphenicol. *Cancer Chemotherapy* 1977;232:121–8.
121. Dutta JK, Santhanam S, Misra BS, Ray SN. Effect of trimethoprim-sulphamethoxazole on vibrio clearance in cholera El Tor: a comparative study. *Trans R Soc Trop Med Hyg* 1978;72:40–2.
122. Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. Cholera. *Lancet.* 2017; pii: S0140-67361730559-7.
123. Neu HC. The crisis in antibiotic resistance. *Science* 1992;257:1064–73.
124. Aminov RI, Mackie RI. Evolution and ecology of antibiotic resistance genes. *FEMS Microbiol Lett* 2007;271:147–61.
125. Verma J, Bag S, Saha B, Kumar P, Ghosh TS, Dayal M, et al. Genomic plasticity associated with antimicrobial resistance in *Vibrio cholerae*. *Proc Natl Acad Sci USA* 2019;11613:6226–31.
126. Wozniak RA, Waldor MK. Integrative and conjugative elements: mosaic mobile genetic elements enabling dynamic lateral gene flow. *Nat Rev Microbiol* 2010;8:552–63.
127. Mhalu FS, Mmari PW, Ijumba J. Rapid emergence of El Tor *Vibrio cholerae* resistant to antimicrobial agents during first six months of fourth cholera epidemic in Tanzania. *Lancet* 1979;18112:345–7.
128. Wang R, Lou J, Liu J, Zhang L, Li J, Kan B. Antibiotic resistance of *Vibrio cholerae* O1 El Tor strains from the seventh pandemic in China, 1961–2010. *Int J Antimicrob Agents* 2012;40:361–4.
129. Towner KJ, Pearson NJ, Mhalu FS, O’Grady F. Resistance to antimicrobial agents of *Vibrio cholerae* El Tor strains isolated during the fourth cholera epidemic in the United Republic of Tanzania. *Bull World Health Organ* 1980;58:747–51.
130. Siddique AK, Salam A, Islam MS, Akram K, Majumdar RN, Zaman K, et al. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma. *Zaire Lancet* 1995;345:359–61.
131. Siddique AK, Baqui AH, Eusof A, Haider K, Hossain MA, Bashir I, et al. Survival of classic cholera in Bangladesh. *Lancet* 1991;337:1125–7.
132. Nizami SQ, Farooqui BJ. Cholera in children in Karachi from 1990 through 1995: a study of cases admitted to a tertiary care hospital. *J Pak Med Assoc* 1998;48:171–3.
133. Yu L, Zhou Y, Wang R, Lou J, Zhang L, Li J, et al. Multiple antibiotic resistance of *Vibrio cholerae* serogroup O139 in China from 1993 to 2009. *PLoS ONE* 2012;7:e38633.
134. Kuma GK, Opintan J, Sackey SO, Opintan J. Antibiotic resistance patterns amongst clinical *Vibrio cholerae* O1 isolates from Accra, Ghana. 2014. *Int J Infect Control* 2014, v10:i3.
135. Mohapatra H, Mohapatra SS, Mantri CK, Colwell RR, Singh DV. *Vibrio cholerae* non-O1, non-O139 strains isolated before 1992 from Varanasi, India are multiple drug resistant, containing *sxt*, *dfr18* and *aadA5* genes. *Environ Microbiol* 2008;10:866–73.